Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Given Average Recommendation of “Moderate Buy” by Brokerages

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) has been given an average recommendation of “Moderate Buy” by the six brokerages that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $19.00.

A number of equities analysts have recently commented on the stock. Wedbush raised their price objective on shares of Artiva Biotherapeutics from $18.00 to $23.00 and gave the company an “outperform” rating in a research report on Friday, October 17th. Needham & Company LLC reissued a “buy” rating and set a $18.00 price objective on shares of Artiva Biotherapeutics in a report on Friday, October 17th. HC Wainwright raised their target price on shares of Artiva Biotherapeutics from $12.00 to $15.00 and gave the company a “buy” rating in a research note on Wednesday, November 12th. Jefferies Financial Group raised shares of Artiva Biotherapeutics to a “strong-buy” rating in a research note on Tuesday, November 18th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Thursday, October 30th.

Artiva Biotherapeutics Price Performance

ARTV opened at $4.27 on Wednesday. Artiva Biotherapeutics has a 1 year low of $1.47 and a 1 year high of $11.55. The company has a market capitalization of $104.83 million, a price-to-earnings ratio of -1.66 and a beta of 3.10. The firm’s fifty day moving average price is $3.90 and its two-hundred day moving average price is $3.02.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its earnings results on Wednesday, November 12th. The company reported ($0.88) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.04. As a group, equities analysts anticipate that Artiva Biotherapeutics will post -4.95 EPS for the current year.

Insider Activity at Artiva Biotherapeutics

In related news, CEO Fred Aslan sold 25,500 shares of the firm’s stock in a transaction dated Friday, October 17th. The stock was sold at an average price of $6.00, for a total transaction of $153,000.00. Following the transaction, the chief executive officer directly owned 356,721 shares of the company’s stock, valued at approximately $2,140,326. This trade represents a 6.67% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. In the last 90 days, insiders sold 35,062 shares of company stock worth $193,670. 21.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Artiva Biotherapeutics

Several institutional investors have recently bought and sold shares of the stock. Ground Swell Capital LLC purchased a new position in shares of Artiva Biotherapeutics during the second quarter valued at approximately $38,000. Prelude Capital Management LLC bought a new position in Artiva Biotherapeutics in the 3rd quarter worth $41,000. Bank of America Corp DE lifted its position in shares of Artiva Biotherapeutics by 225.8% in the 3rd quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock worth $46,000 after purchasing an additional 11,190 shares during the period. Y Intercept Hong Kong Ltd bought a new stake in shares of Artiva Biotherapeutics during the 2nd quarter valued at about $48,000. Finally, Bridgeway Capital Management LLC purchased a new position in shares of Artiva Biotherapeutics during the second quarter valued at about $53,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.